BiotechnologyImmunic to Participate in Industry and Scientific Conferences in July

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in July:

  • July 5-63rd FORUM Science & Health: Medicine of the Future. Members of Immunic’s management and communications teams will attend this conference in Fürstenfeldbruck near Munich, Germany.

  • July 6-916th World Immune Regulation MeetingEvelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on IMU-935, the company’s potentially best-in-class oral IL-17 inhibitor, in poster and workshop presentations, at this conference in Davos, Switzerland. The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
    • Title: IMU-935, an Orally Available RORgammaT Inverse Agonist in Phase 1 Clinical Trial for Psoriasis, Inhibits Th17-Dependent Autoimmunity without Inducing Thymocyte Aberrations

    • Poster Session: Workshop Poster W12-Autoimmunity
      • Date/Time: Friday, July 8, 20227:30 pm CEST
      • Room: Main Corridor
    • Workshop Title: W12-Autoimmunity
        • Workshop Date/Time: Saturday, July 9, 20222:00 pm – 3:00 pm CEST
        • Presentation Time: 2:10 – 2:20pm CEST
        • Room: Forum

  • July 26-28B & T Cell-Mediated Autoimmune Disease Drug Development Summit. Dr. Peelen will discuss preclinical insights on the company’s oral IL-17 inhibitor, IMU-935, in a presentation entitled, “IMU-935, a potent RORyt inverse agonist, effectively inhibits T helper 17 cells but maintains normal thymocyte development,” on Thursday, July 28, 2022 at 11:00 am EDT, in Boston. The presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

PRNewswire

Leave a Reply

Your email address will not be published. Required fields are marked *